| Overview |
| bs-4841R-FITC |
| TACI Polyclonal Antibody, FITC Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Mouse |
| Human |
| Specifications |
| FITC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human TNFRSF13B/TACI |
| 21-120/293 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Cell membrane |
| TACI; CD267; CD267 antigen; CVID; TNFRSF 13B; TNFRSF 14B;TNFRSF13B; TNFRSF13B protein; TNFRSF14B; Transmembrane activator and CAML interactor; Tumor necrosis factor receptor 13B; Tumor necrosis factor receptor superfamily member 13B. |
| TACI is a lymphocyte specific member of the tumor necrosis factor (TNF) receptor superfamily. It interacts with calcium-modulator and cyclophilin ligand (CAML). The protein binds to both APRIL and BAFF and induces activation of the transcription factors NFAT (nuclear-factor of activated T cells), AP1, and NF kappa B and plays a crucial role in humoral immunity by interacting with a TNF ligand. This gene is located within the Smith Magenis syndrome region on chromosome 17. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz